The investigational PET contrast agent for myocardial perfusion imaging (MPI), flurpiridaz F 18, was found to be superior to MPI with SPECT for assessing coronary artery disease (CAD) in obese patients. The findings were presented yesterday by Lantheus at the American College of Cardiology’s annual scientific session in Chicago. {read more here}